ARTICLE | Company News

"Surprised" Arrowhead responds

October 10, 2014 2:29 AM UTC

Shares of Arrowhead Research Corp. (NASDAQ:ARWR) were off $0.11 to $6.92 on Thursday after the company issued an "open letter" in which it said it was taken "by surprise" by shareholder reaction to publication of an abstract for its HBV therapy ARC-520, indicating "the market clearly expected something different and/or misunderstood the data."

The abstract for presentation at the American Association for the Study of Liver Diseases (AASLD) meeting in November showed that patients receiving 1 mg/kg of ARC-520 had a 39% mean peak knockdown of hepatitis B surface antigen (HBsAg). Those receiving 2 mg/kg had a 51% mean peak knockdown. ...